Researchers at the Perelman School of Medicine at the University of Pennsylvania report that monoclonal antibodies can block GPNMB, an immune-related protein that helps drive the spread of brain cell damage in Parkinson's disease. The findings, published in Neuron, point to GPNMB - short for glycoprotein nonmetastatic melanoma B - as a possible target for a therapy that slows the disease in its earliest stages.
That matters because of a gap in current care. Many people with Parkinson's are diagnosed early, when symptoms are still relatively mild, yet no available treatment slows the underlying progression. Existing options manage symptoms while the disease continues to advance, so a drug aimed at the spreading mechanism itself would address something medicine currently cannot.
Parkinson's affects more than a million people in the United States, with roughly 90,000 new diagnoses each year. Although the cause remains unclear, the disease is known to move through the brain in stages, propelled by abnormal clumps of a neuronal protein called alpha-synuclein. Those clumps build up inside affected neurons, contributing to their dysfunction and death, and are then released and picked up by nearby healthy neurons. As the damage travels from one brain region to the next, symptoms such as tremors and trouble walking or swallowing worsen.
The Penn team frames these as early results rather than a finished therapy - a promising step toward a progression-slowing treatment, not evidence of one. Whether blocking GPNMB translates into measurable benefit for patients will depend on further work.